Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Nanoscope will present at the AAO 2024 Annual Meetingtaking place October 18-21, 2024 in Chicago, Illinois, and the associated Eyecelerator @ AAO 2024and Innovate Retinameetings both taking place on October 17th, 2024. Details for the presentations are as follows:
https://mma.prnewswire.com/media/1333752/Nanoscope_Therapeutics_Logo.jpg
Title:Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to RP: Two-Year TOPLINE Results from a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE)Session:Session PA048 (Retina, Vitreous Original Papers)Session Date: Sunday, October 20th, 2024Session Time: 2:00PM – 3:15 PM CDT (In Person, On Demand)Location:McCormick Place Convention Center, Room S405Presenter:Allen Ho,MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope Therapeutics, Inc.
During his presentation, Dr. Ho will discuss end-of-study topline data from Nanoscope’s RESTORE, arandomized-controlled trial (RCT) of MCO-010 therapy in patients with severe vision loss due to retinitis pigmentosa (RP). RESTORE is the first-ever RCT to show statistically significant visual acuity improvement in this patient population and a key part of the upcoming BLA submission planned for Nanoscope’s RP program.
Session Title: Retina Showcase (Eyecelerator @ AAO 2024)Session Date:Thursday, October 17th, 2024Session Time: 1:15 – 3:00 PM CDTLocation: McCormick Place Convention Center, room E450aPresenter: Samuel Barone, MD, Chief Medical Officer
During his presentation, Dr. Barone will showcase Nanoscope’s next-generation Multi-Characteristic Opsin platform program for patients with geographic atrophy (GA) due to advanced AMD. The program utilizes MCO-020, a next-generation MCO gene therapy, and features Nanoscope’s proprietary spatially targeted, non-viral, optical gene delivery approach. Nanoscope’s GA program is currently in the clinical run-up to a Phase 1/2 trial in GA patients.
Session Title: The Future of Retinal Therapeutics (Innovate Retina)Session Date: October 17th, 2024Session Time: 6:24 PM CDTLocation: InterContinental Chicago Magnificent Mile, Grand BallroomPanelist: Samarendra Mohanty, PhD, President and Chief Scientific Officer
Dr. Mohanty will participate in a panel covering the landscape of cutting-edge therapies in development to address retinal diseases.
AboutNanoscope Therapeutics Inc.Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase2bmulticenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and recently announcedplans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.
Investor Contact:Argot Partners212-600-1902PR@nanostherapeutics.com
https://c212.net/c/img/favicon.png?sn=DA28497&sd=2024-10-15
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024-302273411.html
SOURCE Nanoscope Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=DA28497&Transmission_Id=202410150700PR_NEWS_USPR_____DA28497&DateId=20241015
COMTEX_458815746/1005/2024-10-15T07:00:36